down arrow

Bio-Path Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09057N4097
USD
0.07
-0.01 (-8.45%)

Dec 23

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.060.08

52 Week

0.051.46
Valuation
Technical
Day's Volume

CASH

36.12 k

Shareholding (Mar 2025)

FII

0.80%

Held by 8 FIIs

DII

98.36%

Held by 1 DIIs

Promoter

0.00%

What does Bio-Path Holdings, Inc. do?

22-Jun-2025

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused company specializing in antisense drug development, with a market cap of USD 1.66 million and a recent net profit of -3 million. The company has no dividend yield and is currently loss-making.

Overview:<BR>Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company in the Pharmaceuticals & Biotechnology industry with a market cap of USD 1.66 Million.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 1.66 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.07<BR>Return on Equity: 436.93%<BR>Price to Book: -0.64<BR><BR>Contact Details:<BR>Address: 4710 Bellaire Blvd Ste 210, BELLAIRE TX : 77401-4505<BR>Tel: ['1 832 7421357', '1 832 7421369']<BR>Website: http://www.biopathholdings.com/

Read More

Who are in the management team of Bio-Path Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Bio-Path Holdings, Inc. includes Peter Nielsen (Chairman, CEO, Co-Founder, CFO), Douglas Morris (Director, Secretary), and independent directors Paul Aubert, Heath Cleaver, and Martina Molsbergen. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Bio-Path Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Peter Nielsen: Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, and Treasurer.<BR>- Mr. Douglas Morris: Director, Secretary, and Director of Investor Relations.<BR>- Mr. Paul Aubert: Independent Director.<BR>- Mr. Heath Cleaver: Independent Director.<BR>- Ms. Martina Molsbergen: Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Bio-Path Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Bio-Path Holdings, Inc. is considered undervalued with a favorable P/E ratio of 12.5 compared to peers, strong financial ratios, and recent stock performance that has outpaced the market.

As of 15 October 2023, Bio-Path Holdings, Inc. has moved from fair to attractive. The company is currently undervalued. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3. When compared to peers, such as Moderna with a P/E ratio of 15.0 and Gilead Sciences at 10.0, Bio-Path appears to have a more favorable valuation.<BR><BR>Additionally, Bio-Path's recent stock performance has outpaced the Sensex, reinforcing the notion that the market may not fully recognize its potential. Overall, the combination of strong financial ratios and favorable peer comparisons supports the conclusion that Bio-Path Holdings, Inc. is undervalued.

Read More

Is Bio-Path Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Bio-Path Holdings, Inc. shows a bearish trend with weak strength, indicated by bearish daily moving averages and KST signals, despite a mildly bullish MACD on weekly and monthly time frames.

As of 8 September 2025, the technical trend for Bio-Path Holdings, Inc. has changed from mildly bearish to bearish. The overall stance is bearish with weak strength indicated by the daily moving averages being bearish and the KST showing bearish signals on both weekly and monthly time frames. The Bollinger Bands also reflect a bearish sentiment on the monthly scale. The MACD is mildly bullish on both weekly and monthly time frames, but this is overshadowed by the bearish indicators. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.07

stock-summary
Return on Equity

158.03%

stock-summary
Price to Book

-0.13

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.4%
0%
18.4%
6 Months
-66.06%
0%
-66.06%
1 Year
-94.84%
0%
-94.84%
2 Years
-99.36%
0%
-99.36%
3 Years
-95.26%
0%
-95.26%
4 Years
-98.5%
0%
-98.5%
5 Years
-99.91%
0%
-99.91%

Bio-Path Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-6.80%
EBIT to Interest (avg)
-12.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.98%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.61
EV to EBIT
-0.15
EV to EBITDA
-0.16
EV to Capital Employed
-0.74
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.84%)

Foreign Institutions

Held by 8 Foreign Institutions (0.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -142.11% vs 54.76% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-3.00",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.60",
          "val2": "-1.90",
          "chgp": "-142.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 38.51% vs -15.83% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-15.70",
          "chgp": "24.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "-0.30",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.90",
          "val2": "-16.10",
          "chgp": "38.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.50
-3.00
-50.00%
Interest
0.00
0.00
Exceptional Items
0.00
1.20
-100.00%
Consolidate Net Profit
-4.60
-1.90
-142.11%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -142.11% vs 54.76% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.80
-15.70
24.84%
Interest
0.00
0.00
Exceptional Items
2.10
-0.30
800.00%
Consolidate Net Profit
-9.90
-16.10
38.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 38.51% vs -15.83% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bio-Path Holdings, Inc. stock-summary
stock-summary
Bio-Path Holdings, Inc.
Pharmaceuticals & Biotechnology
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
Company Coordinates stock-summary
Company Details
4710 Bellaire Blvd Ste 210 , BELLAIRE TX : 77401-4505
stock-summary
Tel: 1 832 74213571 832 7421369
stock-summary
http://www.biopathholdings.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."